Meredith L Wallace1, Burcin Simsek2, David J Kupfer3, Holly A Swartz3, Andrea Fagiolini4, Ellen Frank3. 1. Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, United States; Department of Statistics, University of Pittsburgh, Pittsburgh, PA, United States. Electronic address: lotzmj@upmc.edu. 2. Department of Statistics, University of Pittsburgh, Pittsburgh, PA, United States. 3. Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, United States. 4. Department of Molecular Medicine, University of Siena, Italy.
Abstract
BACKGROUND: Individuals diagnosed with bipolar 1 disorder (BP1), bipolar 2 disorder (BP2), or major depressive disorder (MDD) experience varying levels of depressive and (hypo)manic symptoms. Clarifying symptom heterogeneity is meaningful, as even subthreshold symptoms may impact quality of life and treatment outcome. The MOODS Lifetime self-report instrument was designed to capture the full range of depressive and (hypo)manic characteristics. METHODS: This study applied clustering methods to 347 currently depressed adults with MDD, BP2, or BP1 to reveal naturally occurring MOODS subgroups. Subgroups were then compared on baseline clinical and demographic characteristics and as well as depressive and (hypo)manic symptoms over twenty weeks of treatment. RESULTS: Four subgroups were identified: (1) high depressive and (hypo)manic symptoms (N=77, 22%), (2) moderate depressive and (hypo)manic symptoms (N=115, 33%), (3) low depressive and moderate (hypo)manic symptoms (N=82, 24%), and (4) low depressive and (hypo)manic symptoms (N=73, 21%). Individuals in the low depressive/moderate (hypo)manic subgroup had poorer quality of life and greater depressive symptoms over the course of treatment. Individuals in the high and moderate severity subgroups had greater substance use, longer duration of illness, and greater (hypo)manic symptoms throughout treatment. Treatment outcomes were primarily driven by individuals diagnosed with MDD. LIMITATIONS: The sample was drawn from three randomized clinical trials. Validation is required for this exploratory study. CONCLUSIONS: After validation, these subgroups may inform classification and personalized treatment beyond categorical diagnosis.
BACKGROUND: Individuals diagnosed with bipolar 1 disorder (BP1), bipolar 2 disorder (BP2), or major depressive disorder (MDD) experience varying levels of depressive and (hypo)manic symptoms. Clarifying symptom heterogeneity is meaningful, as even subthreshold symptoms may impact quality of life and treatment outcome. The MOODS Lifetime self-report instrument was designed to capture the full range of depressive and (hypo)manic characteristics. METHODS: This study applied clustering methods to 347 currently depressed adults with MDD, BP2, or BP1 to reveal naturally occurring MOODS subgroups. Subgroups were then compared on baseline clinical and demographic characteristics and as well as depressive and (hypo)manic symptoms over twenty weeks of treatment. RESULTS: Four subgroups were identified: (1) high depressive and (hypo)manic symptoms (N=77, 22%), (2) moderate depressive and (hypo)manic symptoms (N=115, 33%), (3) low depressive and moderate (hypo)manic symptoms (N=82, 24%), and (4) low depressive and (hypo)manic symptoms (N=73, 21%). Individuals in the low depressive/moderate (hypo)manic subgroup had poorer quality of life and greater depressive symptoms over the course of treatment. Individuals in the high and moderate severity subgroups had greater substance use, longer duration of illness, and greater (hypo)manic symptoms throughout treatment. Treatment outcomes were primarily driven by individuals diagnosed with MDD. LIMITATIONS: The sample was drawn from three randomized clinical trials. Validation is required for this exploratory study. CONCLUSIONS: After validation, these subgroups may inform classification and personalized treatment beyond categorical diagnosis.
Authors: Giovanni B Cassano; Paola Rucci; Ellen Frank; Andrea Fagiolini; Liliana Dell'Osso; M Katherine Shear; David J Kupfer Journal: Am J Psychiatry Date: 2004-07 Impact factor: 18.112
Authors: Andrea Fagiolini; Ellen Frank; Paola Rucci; Giovanni B Cassano; Scott Turkin; David J Kupfer Journal: Bipolar Disord Date: 2007-08 Impact factor: 6.744
Authors: David J Kupfer; David A Axelson; Boris Birmaher; Charlotte Brown; David E Curet; Andrea Fagiolini; Ellen Frank; Edward S Friedman; Victoria J Grochocinski; Patricia R Houck; Amy M Kilbourne; Benoit H Mulsant; Bruce G Pollock; Charles F Reynolds; Mary G Stofko; Holly A Swartz; Michael E Thase; Scott R Turkin; Ellen M Whyte Journal: Psychiatr Serv Date: 2009-07 Impact factor: 4.157
Authors: Gaelle E Doucet; Dongdong Lin; Yuhui Du; Zening Fu; David C Glahn; Vincent D Calhoun; Jessica Turner; Sophia Frangou Journal: NPJ Schizophr Date: 2020-12-04